couter

INOInovio Pharmaceuticals, Inc.

This year, Inovio Pharmaceuticals has to prove it can turn its pipeline into cash — and the next big test is the FDA’s decision on its therapeutic candidates in late November. That’s the event with the highest modeled bull probability at 52%, and it’s the only catalyst in the next 12 months that could push the stock above $2. If the FDA says yes, the stock could rally to $2.00 from its current anchor of $0.90. If not, it could fall to $0.80. Either way, the outcome will define whether Inovio is a biotech with legs or a company stuck in a loop of cash burns and regulatory limbo.

Nov 10, 2026 — Q3 2026 Earnings Release
Chart by TradingView

The schedule

  • Tue10Nov

    Quarterly earnings report with guidance on revenue, expenses, and R&D progress.

  • Thu19Nov

    FDA decision on the approval status of INO's therapeutic candidates.

  • Wed10Feb

    Fourth-quarter earnings report with updated financial guidance and operational performance.

  • Mon15Feb

    Potential strategic partnership or exit opportunity for INO.

  • Wed12May

    First-quarter earnings report with updated financial guidance and operational performance.

  • Wed11Aug

Past

  • Wed30Sep

    Anticipated equity financing to support R&D and operational activities.

  • Wed12Aug

    Actual outcome: Bull

    The FDA completed key steps in its review of the BLA for INO-3107, advancing the PDUFA date to October 30, 2026, and signaling progress toward commercial launch. This regulatory milestone boosted investor confidence in the drug's approval timeline and market potential. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +76.6% from 2026-08-07 to 2026-08-24 (~3.9σ vs typical 10d vol). Target date 2026-08-21 reached; move through 2026-08-24 observed. Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-07: +76.6% from 2026-08-07 (~3.9σ). Target date 2026-08-21 reached; move through 2026-09-07 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-08: +76.6% from 2026-08-07 (~3.9σ). Target date 2026-08-21 reached; move through 2026-09-08 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-08: +76.6% from 2026-08-07 (~3.9σ). Target date 2026-08-21 reached; move through 2026-09-08 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-09: +76.6% from 2026-08-07 (~3.9σ). Target date 2026-08-21 reached; move through 2026-09-09 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-10: +76.6% from 2026-08-07 (~3.9σ). Target date 2026-08-21 reached; move through 2026-09-10 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-14: +76.6% from 2026-08-07 (~3.9σ). Target date 2026-08-21 reached; move through 2026-09-14 observed.

    The FDA completed key steps in its review of the BLA for INO-3107, advancing the PDUFA date to October 30, 2026, and signaling progress toward commercial launch. This regulatory milestone boosted investor confidence in the drug's approval timeline and market potential. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +76.6% from 2026-08-07 to 2026-08-24 (~3.9σ vs typical 10d vol). Target date 2026-08-21 reached; move through 2026-08-24 observed. Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-07: +76.6% from 2026-08-07 (~3.9σ). Target date 2026-08-21 reached; move through 2026-09-07 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-08: +76.6% from 2026-08-07 (~3.9σ). Target date 2026-08-21 reached; move through 2026-09-08 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-08: +76.6% from 2026-08-07 (~3.9σ). Target date 2026-08-21 reached; move through 2026-09-08 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-09: +76.6% from 2026-08-07 (~3.9σ). Target date 2026-08-21 reached; move through 2026-09-09 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-10: +76.6% from 2026-08-07 (~3.9σ). Target date 2026-08-21 reached; move through 2026-09-10 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-14: +76.6% from 2026-08-07 (~3.9σ). Target date 2026-08-21 reached; move through 2026-09-14 observed.

  • Wed12Aug

    Actual outcome: Bull · $1.30 at outcome

    Inovio reported Q2 2026 results with an EPS actual of -0.07, matching the estimate. The key focus was on the FDA advancing its review of the BLA for INO-3107 with a PDUFA date of October 30, 2026, and commercial preparations for a potential launch. The stock rallied due to positive developments around the FDA review and commercialization progress, despite the EPS beat.

    Inovio reports Q2 2026 results with a hyper-focus on cash runway and burn rate as liquidity shrinks ahead of the October FDA decision.

  • Wed13May

    Actual outcome: Bear · $1.10 at outcome

    Inovio reported Q1 2026 earnings that met EPS estimates, highlighting reduced operating expenses and a cash runway projected into the first quarter of 2027. Despite these stabilizing financial metrics and positive Phase 3 results for VGX-3100 from its Chinese partner ApolloBio, the stock fell 17.9% over the outcome period. The decline reflects a lack of immediate commercial catalysts, as investors opted to step to the sidelines while awaiting the critical, binary FDA approval decision for INO-3107 expected in October 2026.

    Q1 2026 earnings for Inovio Pharmaceuticals, Inc. will focus less on revenue (still de minimis) and more on burn rate, cash runway, and any restructuring or pipeline reprioritization, with the stock starting from $1.09 and an expected post-event range between $1.40 in a constructive scenario and $0.80 if results raise going-concern or near-term financing concerns.